ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint742,806 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryBaselAdagene AG
Adagene AG Logo
Verified· 2 sources

Adagene AG

Summary

About the company

The core activity of Adagene is the discovery and development of therapeutic antibodies for the treatment of cancer. The company focuses on developing antibodies with novel mechanisms of action (MOAs) and utilizes its own technology platform, which is based on the dynamic precision of antibodies. Adagene develops antibodies for various applications, including cancer immunotherapy, and has partnerships with global companies to leverage its technology and develop new treatment options.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered6
Antibody discovery and design platform (Dynamic Precision Library)
Antibody discovery and design platform with NEObody, SAFEbody and POWERbody for precise binding, masking and local activation in the tumor microenvironment.
NEObody
Antibody technology with dynamic binding sites for unique epitopes and new mechanisms of action; foundation for programs such as ADG116 and ADG106.
SAFEbody
Masked antibody and NEObody technology with selective activation in the tumor microenvironment to potentially reduce on-target/off-tumor toxicity.
POWERbody
Antibody-based technology for SAFE bispecific T-cell engagers, SAFE antibody-drug conjugates and other modalities with local activation in the tumor microenvironment.
Oncology antibody programs
Clinical and preclinical development programs for cancer, including ADG126, ADG116, ADG106 and additional IND-enabling preclinical programs.

Knowledge

No knowledge articles yet

Once Adagene AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Adagene AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Adagene AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Adagene AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Aeschengraben 29
4051 Basel

At a glance

Legal form
Corporation
UID
CHE-275.564.144
Founded
2023 · 3 years
Last commercial register change
November 30, 2023
Employees
101 to 500

Similar companies

CP
Corden Pharma International Switzerland GmbH
Basel
MP
Mepha Pharma AG
Basel
SG
Sandoz Group AG
Basel
SA
Sandoz AG
Basel